drugset / Trial / NCT02466815

A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets

NCT02466815

Phase 1 Completed 12 enrolled Janssen Research & Development, LLC
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to assess the relative bioavailability of 2 prototype G-025 tablets compared with the current G-018 tablet.

Timeline

Start
2015-06
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Erdafitinib Small molecule 10 mg

Indications

No indication recorded.